An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

C. Haslund; A. Muhic; S. Lukacova; B. Lund; Y. Lassen-Ramshad; Mette Meyer; M. Roland; Hans Skovgaard Poulsen

doi:10.1093/neuonc/now188.017

An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

C. Haslund, A. Muhic, S. Lukacova, B. Lund, Y. Lassen-Ramshad, Mette Meyer, M. Roland, Hans Skovgaard Poulsen

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Neuro-Oncology
Vol/bind	18
Sider (fra-til)	iv6
Antal sider	1
ISSN	1522-8517
DOI	https://doi.org/10.1093/neuonc/now188.017
Status	Udgivet - 1 okt. 2016
Begivenhed	EANO 2016 Meeting - Mannheim, Tyskland Varighed: 12 okt. 2016 → 16 okt. 2016 Konferencens nummer: 12 https://www.eano.eu/eano2016/welcome/

Konference

Konference	EANO 2016 Meeting
Nummer	12
Land/Område	Tyskland
By	Mannheim
Periode	12/10/2016 → 16/10/2016
Internetadresse	https://www.eano.eu/eano2016/welcome/

Emneord

Oncology
Neurosciences & Neurology

Adgang til dokumentet

10.1093/neuonc/now188.017

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Haslund, C., Muhic, A., Lukacova, S., Lund, B., Lassen-Ramshad, Y., Meyer, M., Roland, M., & Poulsen, H. S. (2016). An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan. Neuro-Oncology, 18, iv6. https://doi.org/10.1093/neuonc/now188.017

@article{db7c450da8fd42dfb1f4d91530d7e1d5,

title = "An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan",

keywords = "Oncology, Neurosciences & Neurology",

author = "C. Haslund and A. Muhic and S. Lukacova and B. Lund and Y. Lassen-Ramshad and Mette Meyer and M. Roland and Poulsen, {Hans Skovgaard}",

year = "2016",

month = oct,

day = "1",

doi = "10.1093/neuonc/now188.017",

language = "English",

volume = "18",

pages = "iv6",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

note = "EANO 2016 Meeting ; Conference date: 12-10-2016 Through 16-10-2016",

url = "https://www.eano.eu/eano2016/welcome/",

}

Haslund, C, Muhic, A, Lukacova, S, Lund, B, Lassen-Ramshad, Y, Meyer, M, Roland, M & Poulsen, HS 2016, 'An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan', Neuro-Oncology, bind 18, s. iv6. https://doi.org/10.1093/neuonc/now188.017

An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan. / Haslund, C.; Muhic, A.; Lukacova, S. et al.
I: Neuro-Oncology, Bind 18, 01.10.2016, s. iv6.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan

AU - Haslund, C.

AU - Muhic, A.

AU - Lukacova, S.

AU - Lund, B.

AU - Lassen-Ramshad, Y.

AU - Meyer, Mette

AU - Roland, M.

AU - Poulsen, Hans Skovgaard

N1 - Conference code: 12

PY - 2016/10/1

Y1 - 2016/10/1

KW - Oncology

KW - Neurosciences & Neurology

U2 - 10.1093/neuonc/now188.017

DO - 10.1093/neuonc/now188.017

M3 - Conference abstract in journal

SN - 1522-8517

VL - 18

SP - iv6

JO - Neuro-Oncology

JF - Neuro-Oncology

T2 - EANO 2016 Meeting

Y2 - 12 October 2016 through 16 October 2016

ER -

Haslund C, Muhic A, Lukacova S, Lund B, Lassen-Ramshad Y, Meyer M et al. An Open-Labelled, Randomized Phase II Study in Patients with Recurrent Glioblastoma Multiforme Comparing Progression Free Survival of Alecsat (Autologous Lymphoid Effector Cells Specific Against Tumour-Cells) Versus Bevacizumab/irinotecan. Neuro-Oncology. 2016 okt. 1;18:iv6. doi: 10.1093/neuonc/now188.017